Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided for the purpose of scientific exchange.

The website is not country specific and may therefore contain information that is not applicable in your country, thus you may find information concerning study drugs or therapeutic uses that have not been approved by drug regulatory agencies. This website is not intended to promote in any way, any use, either approved, or unapproved, of a Novo Nordisk product or of any other product or serve as basis for any treatment decision or action. Please always refer to Summary of Product Characteristics (product label) as approved by regulatory authorities in your country or contact Novo Nordisk for further information.

Furthermore, the site is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. Only a physician can determine whether a specific product is correct for a particular patient. Novo Nordisk accepts no liability for the accuracy, completeness or use of this information, and disclaims any liability to update the information contained on this site.

By accessing this website you accept this legal notice and expressly confirm your status as a healthcare professional.

MDS
Virtual
2021
Symposium
Date and time:
17.09.2021 at 09:00 - CDT
Type:
Corporate Event
Speakers:
Roger Barker; Gesine Paul-Visse; Malin Parmar;
Congress:
International Congress of Parkinson's Disease and Movement Disorders (MDS)
The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The MDS Virtual Congress 2021 focuses on delivering three major missions. First, to disseminate knowledge about Movement Disorders. Second, to promote research into causes, prevention and treatment of Movement Disorders. Third, for the purposes of favourably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance. Novo Nordisk is driving changes in regenerative medicine through partnerships, with the purpose to improve the lives of patients suffering from serious chronic diseases by developing innovative cell therapies. We have decades of stem cell experience to share, as well as the tools and capabilities to bring an idea all the way from discovery to the market, and has an extensive network of collaborative partnerships driving many exciting cell therapy projects forward at biotech speed with pharma quality. Please join us for an exciting symposium session on Advancing Science with Cell Therapies for the Treatment of Parkinson's Disease at the MDS Virtual Congress 2021.

Welcome and Introduction

Translating Experimental Preclinical Findings to the Clinic

The Clinical Trials of Dopamine Cell Therapies for PD

Developing a Stem Cell Based Therapy for Parkinson’s Disease

Panel Discussion

Symposium close

Roger Barker

University of Cambridge, Cambridge, United Kingdom


Roger Barker is the Professor of Clinical Neuroscience at the University of Cambridge and a Consultant Neurologist at the Addenbrooke’s Hospital Cambridge. He is a PI in the MRC-Wellcome Stem Cell Institute in Cambridge and Director of the MRC funded UKRMP Stem and Engineered cell hub.

 

Professor Barker’s research seeks to better define the clinical heterogeneity of two common neurodegenerative disorders of the CNS- namely Parkinson’s and Huntington’s disease. This has helped him define the best way to take new therapies into the clinic including novel experimental therapeutics. 


Read full bio

Gesine Paul-Visse

Lund University, Lund, Sweden


Gesine Paul-Visse is a consultant neurologist and professor of Neurology at Lund University (LU) and Skåne University Hospital, Sweden.  She trained at the Charité in Berlin, UMDS in London and St Andrews University, Scotland. Attracted by Lund as a worldwide pioneering center for neurotransplantation, she joined the lab of Prof. Patrik Brundin supported by an EU Marie Curie postdoc fellowship. Since 2011, she leads a preclinical research group “Translational Neurology” at LU with a focus to understand mechanisms of neurodegenerative disorders, in particular how neurovascular changes contribute to neurodegeneration.

 

Bridging the lab and the clinic, Gesine Paul-Visse is a clinical research fellow in at the Wallenberg Center for Molecular Medicine and also investigator in several clinical trials addressing the neurorestorative effect of growth factors and cell transplantation in Parkinson’s disease. Her vision is to contribute to the development of therapies not only leading to therapeutic improvement but structural regeneration.


Read full bio

Malin Parmar

Lund University, Lund, Sweden


Malin Parmar is a professor in cellular neuroscience at Lund University in Sweden and a New York Stem Cell Foundation – Robertson investigator. Together with her lab she has shown in a series of high-profile publications how human fibroblasts can be converted into neurons, how glial cells can be reprogrammed into neurons in vivo, and how functional dopamine neurons can be generated from human embryonic stem cells.

 

Professor Parmar is the recipient of an ERC starting grant and an ERC Consolidator grant. Her research has a strong translational focus, she leads the European effort STEM-PD, designed to bring stem cell-derived dopamine neurons to clinical trials, and she collaborates within European and International networks as well as Industry partners to develop new, cell-based therapies for Brain Repair with focus on Parkinson’s Disease.


Read full bio